Parkinson’s Disease – the Debate on the Clinical Phenomenology, Aetiology, Pathology and Pathogenesis
暂无分享,去创建一个
Yoav Ben-Shlomo | John Hardy | Trevor W. Robbins | David Brooks | Huw R. Morris | Michel Goedert | T. Robbins | J. Hardy | D. Brooks | D. Burn | M. Goedert | Y. Ben-Shlomo | P. Bolam | H. Morris | J. Hindle | P. Jenner | David Burn | Peter Jenner | Paul Bolam | John V. Hindle | J. Hardy
[1] J. Parkinson. An Essay on the Shaking Palsy , 2002 .
[2] J. Langston,et al. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. , 1983, Science.
[3] Niall Quinn,et al. Young onset Parkinson's disease , 1987, Movement disorders : official journal of the Movement Disorder Society.
[4] W. Gibb,et al. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. , 1988, Journal of neurology, neurosurgery, and psychiatry.
[5] C. Marsden,et al. 'Frontal' cognitive function in patients with Parkinson's disease 'on' and 'off' levodopa. , 1988, Brain : a journal of neurology.
[6] A. H. V. Schapira,et al. MITOCHONDRIAL COMPLEX I DEFICIENCY IN PARKINSON'S DISEASE , 1989, The Lancet.
[7] Peter L. Lantos,et al. Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome) , 1989, Journal of the Neurological Sciences.
[8] C. Marsden,et al. Fronto-striatal cognitive deficits at different stages of Parkinson's disease. , 1992, Brain : a journal of neurology.
[9] Nir Giladi,et al. Occurrence of Parkinson's syndrome in type I Gaucher disease. , 1996, QJM : monthly journal of the Association of Physicians.
[10] Robert L. Nussbaum,et al. Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .
[11] Roger Kurlan,et al. A survey of antidepressant drug use in Parkinson's disease , 1997, Neurology.
[12] A. Arnsten,et al. Catecholamine regulation of the prefrontal cortex , 1997, Journal of psychopharmacology.
[13] M G Spillantini,et al. Alpha-synuclein in Lewy bodies. , 1997, Nature.
[14] M. L. Schmidt,et al. α-Synuclein in Lewy bodies , 1997, Nature.
[15] S E Ide,et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. , 1997, Science.
[16] J Q Trojanowski,et al. Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble α‐synuclein , 1998, Annals of neurology.
[17] S. Tsuji,et al. Alpha-synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy. , 1998, Neuroscience letters.
[18] A Klug,et al. Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[19] Hitoshi Takahashi,et al. α-Synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy , 1998, Neuroscience Letters.
[20] S. Minoshima,et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism , 1998, Nature.
[21] Nigel J. Cairns,et al. Filamentous α-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies , 1998, Neuroscience Letters.
[22] R. Krüger,et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. , 1998, Nature genetics.
[23] R A Crowther,et al. Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. , 1998, Neuroscience letters.
[24] R A Crowther,et al. alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[25] R. Crowther,et al. α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies , 1998 .
[26] G. Schellenberg,et al. Tau is a candidate gene for chromosome 17 frontotemporal dementia , 1998, Annals of neurology.
[27] Ronald C. Petersen,et al. Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17 , 1998, Nature.
[28] Karl J. Friston,et al. Frontal, midbrain and striatal dopaminergic function in early and advanced Parkinson's disease A 3D [(18)F]dopa-PET study. , 1999, Brain : a journal of neurology.
[29] J. Langston,et al. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine exposure , 1999, Annals of neurology.
[30] E. Tolosa,et al. Significant association between the tau gene A0/A0 genotype and Parkinson's disease , 2000, Annals of neurology.
[31] M. Goedert,et al. The α‐Synucleinopathies: Parkinson's Disease, Dementia with Lewy Bodies, and Multiple System Atrophy , 2000 .
[32] M. Farrer,et al. Distinctive neuropathology revealed by α-synuclein antibodies in hereditary parkinsonism and dementia linked to chromosome 4p , 2000, Acta Neuropathologica.
[33] B. Ghetti,et al. Frontotemporal Dementia and Parkinsonism Linked to Chromosome 17 , 2011 .
[34] L. Mucke,et al. beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[35] Makoto Hashimoto,et al. β-Amyloid peptides enhance α-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[36] V Kaasinen,et al. Increased frontal [(18)F]fluorodopa uptake in early Parkinson's disease: sex differences in the prefrontal cortex. , 2001, Brain : a journal of neurology.
[37] T. Robbins,et al. Enhanced or impaired cognitive function in Parkinson's disease as a function of dopaminergic medication and task demands. , 2001, Cerebral cortex.
[38] G. Dell''Agnello,et al. SSRIs Do Not Worsen Parkinson's Disease: Evidence from an Open-Label, Prospective Study , 2001, Clinical neuropharmacology.
[39] Patrizia Rizzu,et al. Mutations in the DJ-1 Gene Associated with Autosomal Recessive Early-Onset Parkinsonism , 2002, Science.
[40] D. Dickson,et al. Alpha-synuclein studies are negative in postencephalic parkinsonism of von Economo. , 2002, Neurology.
[41] Yoav Ben-Shlomo,et al. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. , 2002, Brain : a journal of neurology.
[42] J. Trojanowski,et al. Initiation and Synergistic Fibrillization of Tau and Alpha-Synuclein , 2003, Science.
[43] N. Bohnen,et al. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. , 2003, Archives of neurology.
[44] Andre Parent,et al. Presence of reactive microglia in monkey substantia nigra years after 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine administration , 2003, Annals of neurology.
[45] D. D. Di Monte. The environment and Parkinson's disease: is the nigrostriatal system preferentially targeted by neurotoxins? , 2003, The Lancet. Neurology.
[46] H. Braak,et al. Staging of brain pathology related to sporadic Parkinson’s disease , 2003, Neurobiology of Aging.
[47] T. Robbins,et al. The cognitive ability of an incident cohort of Parkinson's patients in the UK. The CamPaIGN study. , 2004, Brain : a journal of neurology.
[48] Andrew Lees,et al. Cloning of the Gene Containing Mutations that Cause PARK8-Linked Parkinson's Disease , 2004, Neuron.
[49] Thomas Meitinger,et al. Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology , 2004, Neuron.
[50] J. Hoenicka,et al. The new mutation, E46K, of α‐synuclein causes parkinson and Lewy body dementia , 2004, Annals of neurology.
[51] R. Nussbaum,et al. Hereditary Early-Onset Parkinson's Disease Caused by Mutations in PINK1 , 2004, Science.
[52] T. Robbins,et al. Planning ability in Parkinson's disease is influenced by the COMT val158met polymorphism , 2004, Movement disorders : official journal of the Movement Disorder Society.
[53] Günther Deuschl,et al. Rivastigmine for dementia associated with Parkinson's disease. , 2004, The New England journal of medicine.
[54] D W Dickson,et al. Autosomal dominant parkinsonism associated with variable synuclein and tau pathology , 2004, Neurology.
[55] C. Marsden,et al. l-Dopa withdrawal in Parkinson's disease selectively impairs cognitive performance in tests sensitive to frontal lobe dysfunction , 2005, Psychopharmacology.
[56] D. Aarsland,et al. A systematic review of prevalence studies of dementia in Parkinson's disease , 2005, Movement disorders : official journal of the Movement Disorder Society.
[57] Houeto Jean-Luc. [Parkinson's disease]. , 2022, La Revue du praticien.
[58] R. Kardon,et al. Frontotemporal dementia and parkinsonism linked to chromosome 17. , 2011, Folia neuropathologica.
[59] T. Robbins,et al. Heterogeneity of Parkinson’s disease in the early clinical stages using a data driven approach , 2005, Journal of Neurology, Neurosurgery & Psychiatry.
[60] M. Farrer,et al. Parkinsonism, Lrrk2 G2019S, and tau neuropathology , 2006, Neurology.
[61] K. Chaudhuri,et al. Non-motor symptoms of Parkinson's disease: diagnosis and management , 2006, The Lancet Neurology.
[62] I. McKeith,et al. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease , 2006, Movement disorders : official journal of the Movement Disorder Society.
[63] U. Mosimann,et al. Orthostatic hypotension in Parkinson's disease: association with cognitive decline? , 2006, International journal of geriatric psychiatry.
[64] M. Breteler,et al. Epidemiology of Parkinson's disease , 2006, The Lancet Neurology.
[65] Anette Schrag,et al. Epidemiological, clinical, and genetic characteristics of early-onset parkinsonism , 2006, The Lancet Neurology.
[66] D. Aarsland,et al. Changes in motor subtype and risk for incident dementia in Parkinson's disease , 2006, Movement disorders : official journal of the Movement Disorder Society.
[67] M. Ban,et al. Tau and alpha-synuclein in susceptibility to, and dementia in, Parkinson's disease. , 2007, Annals of neurology.
[68] T. Robbins. Shifting and stopping: fronto-striatal substrates, neurochemical modulation and clinical implications , 2007, Philosophical Transactions of the Royal Society B: Biological Sciences.
[69] G. Demakis. The neuropsychology of Parkinson's disease. , 2007, Disease-a-month : DM.
[70] D. Brooks. Imaging Non-Dopaminergic Function in Parkinson’s Disease , 2007, Molecular Imaging and Biology.
[71] T. Robbins,et al. Evolution of cognitive dysfunction in an incident Parkinson's disease cohort. , 2007, Brain : a journal of neurology.
[72] Elisabet Englund,et al. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation , 2008, Nature Medicine.
[73] A. Siderowf,et al. Premotor Parkinson's disease: Clinical features, detection, and prospects for treatment , 2008, Annals of neurology.
[74] N. Hattori,et al. CLINICOPATHOLOGIC STUDY OF A SNCA GENE DUPLICATION PATIENT WITH PARKINSON DISEASE AND DEMENTIA , 2008, Neurology.
[75] R. Hauser,et al. Lewy body–like pathology in long-term embryonic nigral transplants in Parkinson's disease , 2008, Nature Medicine.
[76] D. Dickson,et al. Clinical, neuropathological and genotypic variability in SNCA A53T familial Parkinson’s disease , 2008, Acta Neuropathologica.
[77] L. Defebvre,et al. Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: A double‐blind, randomized, placebo‐controlled study , 2008, Movement disorders : official journal of the Movement Disorder Society.
[78] D. Aarsland,et al. A systematic review of prevalence studies of depression in Parkinson's disease , 2008, Movement disorders : official journal of the Movement Disorder Society.
[79] P. Mcgeer,et al. Glial reactions in Parkinson's disease , 2008, Movement disorders : official journal of the Movement Disorder Society.
[80] Sonja W. Scholz,et al. Genome-Wide Association Study reveals genetic risk underlying Parkinson’s disease , 2009, Nature Genetics.
[81] Thomas Gasser,et al. Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria , 2009, The Lancet Neurology.
[82] V. Haroutunian,et al. The neuropathological basis for depression in Parkinson's disease. , 2009, Parkinsonism & related disorders.
[83] Y Ben-Shlomo,et al. The effect of onset age on the clinical features of Parkinson’s disease , 2009, European journal of neurology.
[84] A. Singleton,et al. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. , 2009, Brain : a journal of neurology.
[85] T Revesz,et al. A clinico-pathological study of subtypes in Parkinson's disease. , 2009, Brain : a journal of neurology.
[86] Nicholas W. Wood,et al. Genetic Variants of the α-Synuclein Gene SNCA Are Associated with Multiple System Atrophy , 2009, PloS one.
[87] Sonja W. Scholz,et al. SNCA variants are associated with increased risk for multiple system atrophy , 2009, Annals of neurology.
[88] Thomas Foltynie,et al. The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. , 2009, Brain : a journal of neurology.
[89] A. Strafella,et al. Impulsive and compulsive behaviors in Parkinson's disease , 2009, Movement disorders : official journal of the Movement Disorder Society.
[90] Nick C Fox,et al. Revising the definition of Alzheimer's disease: a new lexicon , 2010, The Lancet Neurology.
[91] J. Hardy,et al. Genetic Analysis of Pathways to Parkinson Disease , 2010, Neuron.
[92] R. Youle,et al. Mechanisms of mitophagy , 2010, Nature Reviews Molecular Cell Biology.
[93] A. Goris,et al. Association of the human leucocyte antigen region with susceptibility to Parkinson's disease , 2010, Journal of Neurology, Neurosurgery & Psychiatry.
[94] Markus Tolnay,et al. The propagation of prion-like protein inclusions in neurodegenerative diseases , 2010, Trends in Neurosciences.
[95] J. Nutt,et al. Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson’s disease , 2010, Nature Genetics.
[96] Yusuke Nakamura,et al. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease , 2009, Nature Genetics.
[97] G. Lewis,et al. Efficacy and acceptability of selective serotonin reuptake inhibitors for the treatment of depression in Parkinson's disease: a systematic review and meta-analysis of randomized controlled trials , 2010, BMC neurology.
[98] Angie A. Kehagia,et al. Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease , 2010, The Lancet Neurology.
[99] Y. Ben-Shlomo,et al. The motor phenotype of Parkinson's disease in relation to age at onset , 2011, Movement disorders : official journal of the Movement Disorder Society.
[100] W. Poewe,et al. The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the non‐motor symptoms of Parkinson's disease , 2011, Movement disorders : official journal of the Movement Disorder Society.
[101] M. Farrer,et al. MAPT H1 haplotype is a risk factor for essential tremor and multiple system atrophy , 2011, Neurology.
[102] E. Waxman,et al. E46K Human α-Synuclein Transgenic Mice Develop Lewy-like and Tau Pathology Associated with Age-dependent, Detrimental Motor Impairment* , 2011, The Journal of Biological Chemistry.
[103] W. Westbroek,et al. Exploring the link between glucocerebrosidase mutations and parkinsonism. , 2011, Trends in molecular medicine.
[104] Constantinos Kallis,et al. Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important? , 2011, Brain : a journal of neurology.
[105] J. Stockman. Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease , 2011 .
[106] Mohamad Saad,et al. Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies , 2011, The Lancet.
[107] D. Burn,et al. Parkinson's disease: The quintessential neuropsychiatric disorder , 2011, Movement disorders : official journal of the Movement Disorder Society.
[108] John L. Robinson,et al. Neuropathologic substrates of Parkinson disease dementia , 2012, Annals of neurology.
[109] J. Holton,et al. The neuropathology, pathophysiology and genetics of multiple system atrophy , 2012, Neuropathology and applied neurobiology.
[110] A. Siderowf,et al. Tricyclic antidepressants delay the need for dopaminergic therapy in early Parkinson's disease , 2012, Movement disorders : official journal of the Movement Disorder Society.
[111] M. Schwarzbold,et al. Anxiety in Parkinson’s disease: A critical review of experimental and clinical studies , 2012, Neuropharmacology.
[112] John Hardy,et al. The spread of neurodegenerative disease. , 2012, The New England journal of medicine.
[113] Harry LeVine,et al. Corruption and Spread of Pathogenic Proteins in Neurodegenerative Diseases* , 2012, The Journal of Biological Chemistry.
[114] J. Hardy,et al. Glucocerebrosidase Deficiency in Substantia Nigra of Parkinson Disease Brains , 2012, Annals of neurology.
[115] S. Sawcer,et al. Systematic Review and UK‐Based Study of PARK2 (parkin), PINK1, PARK7 (DJ‐1) and LRRK2 in early‐onset Parkinson's disease , 2012, Movement disorders : official journal of the Movement Disorder Society.
[116] Roger A. Barker,et al. Cognitive Impairment in Parkinson's Disease: The Dual Syndrome Hypothesis , 2012, Neurodegenerative Diseases.
[117] Miratul M. K. Muqit,et al. PINK1 is activated by mitochondrial membrane potential depolarization and stimulates Parkin E3 ligase activity by phosphorylating Serine 65 , 2012, Open Biology.
[118] D. Dickson. Parkinson's disease and parkinsonism: neuropathology. , 2012, Cold Spring Harbor perspectives in medicine.
[119] C. Christine,et al. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease , 2012, Neurology.
[120] O. Levy,et al. The neuropathology of genetic Parkinson's disease , 2012, Movement disorders : official journal of the Movement Disorder Society.
[121] J. Trojanowski,et al. Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice , 2012, The Journal of experimental medicine.
[122] M. Ban,et al. Glucocerebrosidase mutations influence the natural history of Parkinson's disease in a community-based incident cohort. , 2013, Brain : a journal of neurology.
[123] Christos Proukakis,et al. A novel α-synuclein missense mutation in Parkinson disease , 2013, Neurology.
[124] H. Braak,et al. 100 years of Lewy pathology , 2013, Nature Reviews Neurology.
[125] J. Hardy,et al. α-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson’s disease and multiple system atrophy? , 2013, Acta Neuropathologica.
[126] E. Katunina,et al. [Epidemiology of Parkinson's disease]. , 2013, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova.